Bayer Aktiengesellschaft (WSE:BAY)
Poland · Delayed Price · Currency is PLN | Market Cap | 157.39B +52.8% |
| Revenue (ttm) | 194.35B -2.9% |
| Net Income | -9.26B |
| EPS | -9.43 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 8.45 |
| Dividend | 0.47 (0.28%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 17 |
| Open | 159.05 |
| Previous Close | 164.95 |
| Day's Range | 159.05 - 159.05 |
| 52-Week Range | 103.62 - 198.18 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 12, 2026 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge... [Read more]
Financial Performance
In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer
Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer are benefiting from innovation, pipeline growth and strong demand in key therapies.
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Trial
Olema Pharmaceuticals (OLMA) Teams Up with Bayer for Clinical Trial
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
Olema Oncology announces collaboration, supply agreement with Bayer
Olema Pharmaceuticals announced a clinical trial collaboration and supply agreement with Bayer AG (BAYRY) to evaluate OP-3136, Olema’s investigational lysine acetyltransferase 6 inhibitor, in combinat...
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Study to evaluate OP-3136, Olema’s novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; result...
Bayer to present new data across oncology portfolio
Bayer (BAYRY) announced that new data from studies across their oncology portfolio will be presented at the upcoming 2026 American Society of Clinical Oncology, ASCO, Annual Meeting, taking place in…
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer to Present New Data Across Oncology Portfolio.
Bayer announces Priority Review designation for Kerendia
Bayer (BAYRY) announced that the FDA accepted its supplemental new drug application and granted Priority Review designation for Kerendia, which is being investigated for the treatment of adults with t...
Bayer Wins FDA Priority Review For Kerendia In Chronic Kidney Disease With Type 1 Diabetes
LEVERKUSEN (dpa-AFX) - Bayer AG (BYR.L) on Thursday said the U.S. Food and Drug Administration has granted priority review to its supplemental New Drug Application for Kerendia as a treatment for ...
Bayer says FDA grants priority review designation for finerenone
Bayer said on Thursday that the U.S. Food and Drug Administration had accepted its supplemental New Drug Application for finerenone and granted priority review designation.
Bayer's KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review ...
Bayer Aktiengesellschaft Slides: Corporate presentation
Bayer Aktiengesellschaft has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.
Bayer upgraded to Buy from Hold at DZ Bank
DZ Bank upgraded Bayer (BAYRY) to Buy from Hold with a EUR 51 price target
Bayer granted priority review for asundexian by FDA
Bayer (BAYRY) announced that the FDA has accepted the company’s new drug application and granted priority review designation for its investigational oral Factor XIa inhibitor, asundexian, for the prev...
Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention
(RTTNews) - Bayer AG (BAYRY) announced that the U.S. FDA has accepted its NDA and granted Priority Review for Asundexian, an investigational oral Factor Xla (FXla) inhibitor, for the prevention of sec...
Bayer (BAYRY) Receives FDA Priority Review for Asundexian in Stroke Prevention
Bayer (BAYRY) Receives FDA Priority Review for Asundexian in Stroke Prevention
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT'S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) and granted Priori...
EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...
Bayer (BAYRY) Settles Toxic Contamination Claims for $133M
Bayer (BAYRY) Settles Toxic Contamination Claims for $133M
Bayer agrees to pay $133 million for PCB cleanup in two states
Bayer's Monsanto unit on Monday said it would pay at least $133 million to settle Michigan and Rhode Island's claims that the company contaminated the states' natural resources with toxic chemicals ...
Bayer Gets FDA Priority Review For Hyrnuo In First-Line HER2-Mutated Lung Cancer
LEVERKUSEN (dpa-AFX) - Bayer AG (BYR.L) on Monday said the U.S. Food and Drug Administration has granted priority review for Hyrnuo as a first-line treatment for HER2-mutated non-small cell lung c...
Bayer announces HYRNUO sNDA granted Priority Review status by FDA
Bayer (BAYRY) announced that the U.S. Food and Drug Administration has granted HYRNUO Priority Review status for the first-line treatment of adult patients with locally advanced or metastatic non-smal...
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted HYRNUO (sevabertinib) Priority Review status for the first-line treatment of adult patients with locally advanced or ...
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
WHIPPANY, N.J.--(BUSINESS WIRE)--Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol® in Motion, a camp...
Bayer Introduces Midol in Motion, Empowering Menstruators to Find PMS Relief Through Movement
Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol in Motion, a campaign focused on helping people bet...